Pulmonx Announces Closing of up to $60 Million Credit Facility

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG) a conclu une facilité de crédit de cinq ans avec Perceptive Advisors pour jusqu'à 60 millions de dollars le 4 mars 2026. La facilité finance un prêt à terme de 40 millions de dollars tiré à la clôture pour refinancer une dette existante et une option conditionnelle non utilisée de 20 millions de dollars jusqu'à la fin de 2027.

Le prêt est à intérêt uniquement jusqu'à son échéance en 2031, porte un intérêt au taux SOFR à un mois (plancher de 3,75%) plus 7,0%, et permet à l'option de la société d'un intérêt en nature de 2,0% pendant trois ans.

Positive

• $40M term loan drawn to immediately refinance existing debt
• Facility extends debt maturity to 2031, lengthening runway
• Up to $20M additional undrawn capital available through end of 2027
• Interest-only payments until maturity improve near-term cash flow

Negative

• High spread: SOFR+7.0% with a 3.75% floor, increasing borrowing cost
• 2.0% PIK option could raise effective indebtedness if elected
• Additional $20M is contingent on revenue milestones and is not guaranteed

News Market Reaction – LUNG

+11.81% 1.7x vol

22 alerts

+11.81% News Effect

+20.8% Peak Tracked

-2.7% Trough Tracked

+$8M Valuation Impact

$73M Market Cap

1.7x Rel. Volume

On the day this news was published, LUNG gained 11.81%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.8% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $73M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Credit facility size: $60 million Initial term loan: $40 million Undrawn capital option: $20 million +5 more

8 metrics

Credit facility size $60 million Total capacity of new five-year credit facility with Perceptive Advisors

Initial term loan $40 million Drawn at closing to refinance existing debt

Undrawn capital option $20 million Additional capacity available through end of 2027 upon revenue milestones

Interest rate spread Term SOFR + 7.0% Floating rate with 3.75% SOFR floor on new facility

SOFR floor 3.75% Minimum one-month Term SOFR used in interest calculation

PIK interest portion 2.0% Portion of interest that may be paid-in-kind for three years

Interest-only period Until 2031 Facility structured as interest-only until stated maturity

Undrawn option window Through end of 2027 Deadline to access additional $20M conditional tranche

Market Reality Check

Price: $1.61 Vol: Volume 377,136 is at 0.96...

normal vol

$1.61 Last Close

Volume Volume 377,136 is at 0.96x the 20-day average of 391,790, showing typical activity ahead of this news. normal

Technical Shares at $1.53 are trading below the 200-day MA $2.09 and far under the $8.72 52-week high, closer to the $1.31 52-week low.

Peers on Argus

Only one peer from the medical devices group appeared in momentum scans, with VN...

1 Down

Only one peer from the medical devices group appeared in momentum scans, with VNRX moving down about 0.54%. Broader peers show mixed, mostly negative moves, suggesting this credit facility news is likely more company-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 20	Earnings date notice	Neutral	+6.0%	Scheduled Q4 and full-year 2025 results call on March 4, 2026.
Dec 03	Inducement equity grants	Neutral	+13.2%	Large RSU and PSU awards to new executives under 2025 Inducement Plan.
Nov 12	Q3 2025 earnings	Negative	-18.9%	Reported Q3 2025 results with losses and updated full-year 2025 guidance.
Oct 27	Mgmt change & prelim rev	Positive	+26.9%	CEO/CFO changes plus preliminary Q3 2025 revenue of about $21.5M.
Oct 15	Earnings date notice	Neutral	-2.5%	Announcement of upcoming Q3 2025 results release and conference call.

Pattern Detected

Recent news has often produced aligned price reactions, with stronger moves around management changes and earnings results.

Recent Company History

Over the last several months, Pulmonx has reported Q3 2025 results with $21.5M revenue and updated 2025 guidance, and announced significant leadership transitions with new CEO and CFO/COO appointments in October 2025. Earnings-related dates in October 2025 and February 2026 and inducement equity grants in December 2025 also featured. This financing announcement fits a pattern of balance-sheet and leadership repositioning following operating losses and guidance updates.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-24

$200,000,000 registered capacity

An effective Form S-3/A shelf dated Nov 24, 2025 allows Pulmonx to offer up to $200,000,000 of various securities over time, with proceeds earmarked for working capital, R&D, capex and other general corporate purposes. No usage has been recorded in the provided context, but the shelf increases flexibility for future capital raises.

Market Pulse Summary

The stock surged +11.8% in the session following this news. A strong positive reaction aligns with P...

Analysis

The stock surged +11.8% in the session following this news. A strong positive reaction aligns with Pulmonx’s efforts to fortify its balance sheet. The company secured a five-year credit facility of up to $60 million, including a $40 million refinancing draw and a conditional $20 million tranche, with interest-only payments until 2031. Investors may weigh this added flexibility against existing dilution capacity under the $200,000,000 shelf registration when assessing longer-term risk.

Key Terms

term sofr, paid-in-kind, credit facility, form 8-k

4 terms

term sofr financial

"bears interest at a rate equal to one-month Term SOFR (subject to a 3.75% floor)"

Term SOFR is a benchmark interest rate that reflects the cost of borrowing money over a specific period, based on actual transactions in the financial markets. It is used by lenders and borrowers to set the interest rates on loans and financial contracts, helping to ensure rates are fair and transparent. For investors, understanding term SOFR helps gauge borrowing costs and the overall direction of interest rates in the economy.

paid-in-kind financial

"2.0% of which may be “paid-in-kind” at the Company’s option for a period"

Paid-in-kind describes an arrangement where a borrower pays interest or returns not with cash but by issuing more of the same security (extra bonds or shares) or by increasing the loan balance. For investors this matters because it conserves the issuer’s cash but can dilute ownership or increase debt over time, changing expected cash payments, risk and the real value of an investment much like being paid with an IOU instead of cash.

credit facility financial

"announced the closing of a five-year credit facility for up to $60 million"

A credit facility is a flexible loan arrangement that allows a borrower to access funds up to a set limit whenever needed, similar to a company having an overdraft option on a bank account. It matters to investors because it indicates how easily a business can secure cash when required, affecting its ability to manage expenses, invest, or respond to financial challenges.

form 8-k regulatory

"details regarding the new credit agreement are included in the Company’s Form 8-K"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. Not financial advice.

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors.

The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company’s existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027, subject to the achievement of certain revenue milestones. The new facility is interest only until maturity in 2031, and bears interest at a rate equal to one-month Term SOFR (subject to a 3.75% floor) plus 7.0%, 2.0% of which may be “paid-in-kind” at the Company’s option for a period of three years following the closing date.

“This new debt facility immediately strengthens our capital structure,” said Glen French, President and Chief Executive Officer of Pulmonx. “By extending our debt maturity to 2031 with favorable terms, we can shift our focus toward executing our commercial strategy and advancing our key clinical programs to deliver our life-changing treatment to patients with severe emphysema.”

“The Pulmonx Zephyr Valve is a market-leading product backed by robust clinical evidence, global guideline endorsement, and broad reimbursement that fulfills a significant unmet need for severe emphysema patients who often have no other treatment options,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “This financing reflects our confidence in management’s ability to reposition the company for profitable and sustainable growth.”

Further details regarding the new credit agreement are included in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on March 4, 2026.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements about the Company’s expectations regarding the credit facility, including its impact on the Company’s business and financial position, and the Company’s ability to execute its commercial strategy and advance its key clinical programs. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 12, 2025, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^TM Platform, and StratX^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.

Pulmonx^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks and LungTraX^TM is a trademark of Pulmonx Corporation.

About Perceptive Advisors
Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $8 billion across its strategies. For more information about Perceptive, visit www.perceptivelife.com.

Investor Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com

FAQ

What did Pulmonx (LUNG) announce about the March 4, 2026 credit facility?

Pulmonx closed a five-year credit facility for up to $60 million, including a $40 million term loan drawn at closing. According to the company, an additional $20 million may be drawn through 2027 if revenue milestones are met.

How does the new LUNG credit facility affect the company’s debt maturity and cash flow?

The facility extends Pulmonx debt maturity to 2031 and is interest-only until maturity, easing near-term cash outlays. According to the company, this shift lets management focus on commercial execution and clinical programs.

What are the interest terms for Pulmonx’s March 4, 2026 loan (LUNG)?

The loan bears interest at one-month Term SOFR plus 7.0% with a 3.75% floor, and 2.0% may be paid-in-kind for three years. According to the company, these terms reflect the negotiated financing structure with Perceptive Advisors.

Is the additional $20 million in Pulmonx’s LUNG facility guaranteed?

No — the extra $20 million is an unfunded option subject to revenue milestones through end of 2027, so it is not assured. According to the company, draws depend on achieving specified revenue targets.

Who provided the March 4, 2026 credit facility for Pulmonx (LUNG) and what does it signal?

Perceptive Advisors provided the up to $60 million facility, including a $40 million initial draw. According to the company, the financing signals lender confidence and supports repositioning for sustainable growth.